REGENXBIO Inc. (RGNX) Stock

REGENXBIO Inc. (RGNX) is a Healthcare stock trading at $7.79 (as of 2026-06-18), with a market capitalization of $362.40M and a trailing P/E of -1.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

REGENXBIO Inc. is a clinical-stage biotechnology company developing gene therapy candidates designed to deliver therapeutic genes or enable cells to produce disease-relevant proteins or antibodies. Its products are based on its NAV technology platform, including RGX-314 in Phase III for wet age-related macular degeneration and additional programs in earlier clinical and preclinical stages, and it also licenses the platform to other biotechnology and pharmaceutical companies.

Valuation — source: SEC EDGAR (first-party)
Price$7.79
Market Cap$362.40M
P/E Ratio-1.3
EV / EBITDA-1.4
Price / Book17.19
Price / Sales4.13
DCF Value (model)$-40.98
DCF Upside vs Price-625.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$170.44M
Net Margin-113.8%
Return on Equity-1375.6%
Current Ratio2.62
Revenue Growth (YoY)-92.8%
EPS Growth (YoY)-1533.3%
FCF Growth (YoY)-337.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.17 (distress)
Valuation vs Sector & Industry
Stock P/E-1.3
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-106.0%
vs Industry-107.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($48.59M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOCurran Simpson
Employees353
CountryUS
IPO Date2015-09-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Jade Biosciences, Inc. (JBIO)
  • Arvinas, Inc. (ARVN)
  • Fulcrum Therapeutics, Inc. (FULC)
  • Replimune Group, Inc. (REPL)
  • Annexon, Inc. (ANNX)
  • CytomX Therapeutics, Inc. (CTMX)
  • Lexeo Therapeutics, Inc. Common Stock (LXEO)
  • Invivyd, Inc. (IVVD)
RGNX earnings history · RGNX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.